This report provides exclusive insights into the COVID-19 impact on the Pneumococcal Vaccines Market. The detailed analysis provides information about the impact of the outbreak on the demand and supply conditions, trends and forecasts of the Pneumococcal Vaccines Market. Moreover, the impact analysis covers the study of the COVID-19 on the supply chain of Pneumococcal Vaccines Market. The sectoral impact shall provide insights into both short term and long term effects of the pandemic on the related and support industries.
A recent report published by Infinium Global Research on
pneumococcal vaccines market provides in-depth analysis of segments and
sub-segments in the global as well as regional pneumococcal vaccines market.
The study also highlights the impact of drivers, restraints, and macro
indicators on the global and regional pneumococcal vaccines market over the
short term as well as long term. The report is a comprehensive presentation of
trends, forecast and dollar values of global pneumococcal vaccines market. According
to the report, the global pneumococcal vaccines market is projected to grow at
a CAGR of 3.3% over the forecast period of 2019-2025.

Market
Insight
Pneumococcal
diseases are the outcome of infections caused by streptococcus pneumoniae bacteria
commonly known as pneumococcus. The vaccine helps in prevention of pneumococcal
diseases caused by pneumococcus. There are two types of vaccines currently
available pneumococcal conjugate vaccine PCV 10/PCV13 and pneumococcal
polysaccharide vaccine PPSV23. PCV13 is suggested for children between 6 to 18 years
of age and adults with medical conditions.
PPSV23 is administered to population above 65 years and adults, in
certain cases it is given to the infants who are above two years of age. The WHO has suggested pneumococcal conjugate
vaccines in the routine immunization for children.
Rising
prevalence of pneumococcal diseases such as pneumonia, sepsis, and meningitis
is a major driving factor for the growth of pneumococcal vaccines market. The
infection spread though pneumococcus is the main cause of morbidity and
mortality globally. According to NCBI, it is estimated that approximately
335,000 (240,000–460,000) deaths in children aged greater than 5 years have
occurred in 2015 globally. This increases the need for vaccination and drives
the pneumococcal vaccines market.
Additionally, initiatives taken by the government and private
organizations to provide vaccination and new target population leads to the
growth of pneumococcal vaccines market. However, the high cost associated with
the manufacturing of vaccines is restraining the growth of pneumococcal
vaccines market. The new research techniques on vaccines and growing demand
from developing regions are providing opportunities for the growth of
pneumococcal vaccines market in the coming years.
Amongst
the Geographies, North America is anticipated to hold maximum share in the
pneumococcal vaccine market. Increased investment in the R&D sector and
favorable government initiatives are the major factors responsible for the
growth of the market in the North America region. Europe holds the second
largest share in the pneumococcal drug market. Importance aspects of
communicable diseases and threats related to it are heading the growth of the
pneumococcal vaccine market. The Asia Pacific is estimated to witness the
highest growth rate during the forecast period. The growth of this region is
attributed due to growing awareness regarding pneumococcal vaccine and
increasing incidences of pneumonia.
Segment Covered
The report on global pneumococcal vaccines market covers
segments such as product type and distribution channel. On the basis of
product type, the sub-markets include pneumococcal conjugate vaccine, and
pneumococcal polysaccharide vaccine. On the basis of the distribution channel, the
sub-markets include clinics, hospitals, non-governmental organizations, and
government authorities.
Companies Profiled:
The report provides profiles of the companies in the market
such as Bayer AG, GlaxoSmithKline plc, Pfizer Inc., Nuron Biotech Inc., CSL
Ltd., Biomed Pvt. Ltd., Serum Institute of India Pvt. Ltd., Sanofi Pasteur
Inc., JN-International Medical Corporation, and Merck & Co., Inc.
Report Highlights:
The report provides deep insights into the demand forecasts,
market trends, and micro and macro indicators. In addition, this report
provides insights into the factors that are driving and restraining the growth
in this market. Moreover, The IGR-Growth Matrix analysis given in the report
brings an insight into the investment areas that existing or new market players
can consider. The report provides insights into the market using analytical
tools such as Porter's five forces analysis and DRO analysis of pneumococcal
vaccines market. Moreover, the study highlights current market trends and
provides forecast from 2019-2025. We also have highlighted future trends in the
market that will affect the demand during the forecast period. Moreover, the
competitive analysis given in each regional market brings an insight into the
market share of the leading players.